SUBSCRIBE
SUBSCRIBE
News   Business

DNAPrint Genomics Inc. Selects PT-502 Lead Research Compound For Development Of Drug For Treating Depression

July 17, 2006 | 
1 min read
DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced it has confirmed positive results in an animal model for anti-depressant activity for its PT-502 lead compound being developed with the Massachusetts College of Pharmacy and Health Sciences.
Alliances
MORE ON THIS TOPIC
Winding road leads to the light of the lighthouse. Stock vector illustration
Rare diseases
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
July 28, 2026
 · 
2 min read
 · 
Tristan Manalac
Laptop with envelope and document with exclamation mark on screen. Receive notification, alert message, warning, get e-mail, email, spam concepts. Flat design vector illustration
FDA
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy
July 27, 2026
 · 
3 min read
 · 
Heather McKenzie
3D Paper Cut Pair of Lung dotted with yellow tumor bacteria infection spread across on a blue background with no text. Yellow dots as virus infection in the lungs. Vector Illustration.
Business
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
July 27, 2026
 · 
3 min read
 · 
Gabrielle Masson
Easy Way or Shortcut to Business Success. Businessman on the Straight and Complicated Path. vector
C-suite
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
July 27, 2026
 · 
3 min read
 · 
Annalee Armstrong